Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Capital Expenditures (2016 - 2026)

Anika Therapeutics has reported Capital Expenditures over the past 17 years, most recently at $55000.0 for Q1 2026.

Quarterly Capital Expenditures fell 89.04% to $55000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $219000.0 through Mar 2026, down 57.8% year-over-year, with the annual reading at $666000.0 for FY2025, 4.23% up from the prior year.
Capital Expenditures was $55000.0 for Q1 2026 at Anika Therapeutics, down from $630000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $4.6 million in Q2 2024 and troughed at -$5.8 million in Q4 2024.
The 5-year median for Capital Expenditures is $630000.0 (2025), against an average of $134294.1.
Year-over-year, Capital Expenditures crashed 2265.37% in 2022 and then skyrocketed 445.3% in 2024.
A 5-year view of Capital Expenditures shows it stood at -$4.8 million in 2022, then skyrocketed by 42.83% to -$2.8 million in 2023, then tumbled by 108.8% to -$5.8 million in 2024, then skyrocketed by 110.88% to $630000.0 in 2025, then plummeted by 91.27% to $55000.0 in 2026.
Per Business Quant, the three most recent readings for ANIK's Capital Expenditures are $55000.0 (Q1 2026), $630000.0 (Q4 2025), and -$4.3 million (Q3 2025).